

Attorney General and will be spelled out in agreements between the agencies. At present, as of the date when this goes into effect, this Bureau, my Bureau, will leave some 60 positions in Food and Drug Administration laboratories, to do that work for us.

If and when the Justice Department determines that it might be more feasible to have laboratories under the new Bureau, we would then withdraw that supportive effort.

This has already been named—who they are and the positions, this type of thing. They will be left there. And we will continue to use that same facility as we have in the past.

Mr. HOLIFIELD. You see the thing that is troubling me is the break in the line of authority for the complete function. I have always believed that a straight line of authority was better than cross agency authority, because there is always some difference of opinion between agencies.

I think you made a pretty good case where you say if these investigators find heroin and he is only in the drug abuse department, he can't do anything about it. I can understand the welding together of these two enforcement groups so there would be a close play back and forth of information and function.

They may place LSD and heroin surveillance and apprehension maybe in the same officer. Is that what you plan to do?

Dr. LEE. Yes.

Mr. HOLIFIELD. So I can see the strengths of putting those two together. But I am wondering about your access to backup, laboratory analysis, and expert advice resources.

I am wondering if you are going to have an arrangement close enough to maintain the efficiency of the backup laboratories without bureaucratic entanglement.

Mr. FINLATOR. Mr. Congressman, let me say no matter where we have the laboratories, we have got to have them, and we have got to have them every night.

Now, it seems to us that the most prudent thing to do at present is to use already existing laboratories.

Mr. HOLIFIELD. I agree with you.

Mr. FINLATOR. For I must have a laboratory every night. Therefore, we think it is better to leave it at the present time and leave those funds with the Food and Drug Administration under an arrangement where they will do our work for us. So no matter where we put it, it must be done.

Mr. HOLIFIELD. And it must be instantly and readily available.

Mr. FINLATOR. Right; yes, sir.

Mr. HOLIFIELD. This is the thing, in your statement, Mr. Finlator, you mention in one place the contracting—on page 13—one of the most valuable functions of the Bureau is that of contracting for research needed in the area of pharmacology, social, and drug abuse.

As I understand it, now that type of contracting is being done by experts in the field who know something about it and not by enforcement officers.

Mr. FINLATOR. Correct.

Mr. HOLIFIELD. So will that contracting function follow the enforcement personnel into this new Bureau of the Department of Justice or will it stay where it is in the laboratories of HEW?

Mr. FINLATOR. That isn't in the laboratories of HEW.